• Group sales up 26.0% to A$68.2m
• U.S. sales up 25.3% to A$51.7m
• NovoSorb MTX sales up 195.2% to A$6.2m

PolyNovo Limited (ASX: PNV) has reported its half-year audited results for the period ending 31 December 2025, delivering strong commercial performance despite an evolving macro environment. Group sales increased by 26.0% to A$68.2m, with the U.S. market recording a 25.3% rise to A$51.7m and the Rest of World sales growing by 28.3% to A$16.5m. The company's latest advanced wound care product, NovoSorb MTX, achieved exceptional sales growth of 195.2% to A$6.2m following its successful U.S. launch in Q4 2024. While BARDA revenue declined by 62.5% to A$2.0m as expected with the completion of the U.S. Pivotal Trial for full-thickness burns, the group's total revenue, including BARDA, increased by 25.2% to A$75.0m. The company recorded a Net Profit after Tax of A$3,000 and an EBITDA, adjusted for significant items and FX, of A$4.7m, up 82.0% on the prior period. The half-year was marked by key leadership appointments, including the commencement of Bruce Peatey as Chief Executive Officer and Amy Demediuk as Company Secretary and General Counsel, as well as the completion of the additional manufacturing facility in Port Melbourne.

PolyNovo has not provided any high-importance, price-sensitive forward-looking financial metrics in the announcement.

PolyNovo has entered the second half of FY26 with strong momentum, adding more leadership capability, and with multiple initiatives to advance its growth. The company is well positioned, now and into the future, with strong clinical demand, increasingly favourable reimbursement dynamics and an accelerating innovation pipeline.